Becton Dickinson

BD’s moat is built on multiple pillars. Intangible assets: a century-old brand trusted for sterile disposables; long regulatory history in medication management and pharma packaging (score ~80).

Switching costs: very high in Pharmaceutical Systems (primary container/device integrated into drug filings), Pyxis automated dispensing, and Alaris smart pumps; validation and workflow integration create multi-year switching frictions (score ~90).

Network effects: moderate where BD’s connected platforms (Pyxis, Alaris, HemoSphere/analytics) integrate with EMRs and hospital medication workflows; data compounds value but remains secondary to switching costs (score ~55).

Cost advantages: global scale in syringes/needles and expanding U.S. capacity provide procurement and manufacturing leverage; investments in domestic plants enhance reliability and customer preference (score ~85).

Efficient scale: in specimen collection and certain interventional categories where capacity and regulatory complexity deter entry (score ~75). Weighted, this supports a solid multi-moat profile.

Moat erosion risks include China volume-based procurement price pressure, potential hospital budget constraints, and quality/regulatory events if not continuously managed. FDA 510(k) clearance of updated Alaris and the broad hernia mesh settlement have reduced key overhangs.